Related Experiment Video
Updated: Jan 9, 2026
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
Introducing arginine residues into scFv in CAR-T cells shows promising antitumor effects
Shingo Maeta1, Atsushi Fukunaga1, Yuriko Egashira1
1Bio-Diagnostic Reagent Technology Center, Sysmex Corporation, Kobe 651-2271, Japan.
Abstract:
Current research investigating chimeric antigen receptor (CAR)-T cell therapeutics indicates that CAR properties other than intracellular signaling systems, such as high association rate constants and enhanced self-interaction of the antigen-binding domain (ABD), elicit enhanced therapeutic efficacy and are key factors for CAR-T candidates. However, rational strategies to achieve these features are to be established. To develop novel CAR-T cells with these characteristics, ABD was engineered by introducing several arginine residues into the light-chain framework region-3 of the single-chain fragment variable. The mutant CAR-T cells exhibited a higher cell-killing efficacy than that of wild-type cells and superior antitumor effects in mice, prolonged persistence in vivo, and decreased interferon-γ secretion. RNA sequencing revealed differential gene expression profiles between the mutant and wild-type CAR-T cells before and after antigen stimulation. In conclusion, we proposed a design strategy to generate CAR-T cells with high therapeutic efficacy by modulating CAR properties using an arginine cluster.
Insights
Researchers engineered chimeric antigen receptor (CAR)-T cells by adding arginine residues. This CAR-T cell therapy enhancement resulted in superior antitumor effects and prolonged persistence in mice.
Area of Science:
- Immunology
- Biotechnology
- Cancer Research
Background:
- Chimeric antigen receptor (CAR)-T cell therapy shows promise in cancer treatment.
- Enhanced CAR properties, like antigen-binding domain (ABD) interactions, are crucial for efficacy.
- Rational design strategies for these CAR properties are needed.
Purpose of the Study:
- To engineer novel CAR-T cells with improved therapeutic efficacy.
- To investigate the impact of arginine residues within the ABD on CAR-T cell function.
- To establish a design strategy for modulating CAR properties.
Main Methods:
- Engineered the ABD of CAR by introducing arginine residues into the light-chain framework region-3.
- Compared mutant CAR-T cells with wild-type CAR-T cells.
- Utilized RNA sequencing to analyze gene expression profiles.
Main Results:
- Mutant CAR-T cells demonstrated higher cell-killing efficacy and superior antitumor effects in mice.
- Enhanced CAR-T cells exhibited prolonged persistence in vivo.
- Decreased interferon-γ secretion was observed in mutant CAR-T cells.
- Differential gene expression profiles were identified between mutant and wild-type CAR-T cells.
Conclusions:
- A design strategy using an arginine cluster to modulate CAR properties can generate highly effective CAR-T cells.
- Engineering CAR properties, specifically the ABD, is a viable approach to enhance CAR-T cell therapy.
- This study provides a foundation for developing next-generation CAR-T cell therapeutics.
More Related Videos
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
